SUBDIMA: Subclinical Depression in Acute Myocardial Infarction (SUBDIMA25)

Depression is a recognized risk factor for adverse outcomes in patients with acute coronary syndromes. While most studies have focused on major depressive disorder, subclinical depression (defined as PHQ-9 scores between 5 and 9 in the absence of DSM-5 TR criteria for major depression) remains poorly characterized. Its prevalence in patients with a first acute myocardial infarction (AMI) is largely unknown, as are its potential associations with clinical, biological, and psychosocial outcomes.

The SUBDIMA study is a prospective, exploratory, single-center, non-profit clinical investigation conducted at Fondazione Policlinico Universitario A. Gemelli IRCCS. Consecutively admitted patients with a first AMI will undergo systematic screening with the PHQ-9 and a structured clinical assessment to exclude major depression. Based on these evaluations, patients will be classified into two groups: with or without subclinical depression. All participants will be followed for 12 months, with visits at baseline, 3 months, and 12 months, and intermediate phone contacts at 6 and 9 months.

The primary aim of the study is descriptive: to estimate the prevalence of subclinical depression in this population. Secondary, exploratory aims are to examine potential associations between subclinical depression and:

* inflammatory and metabolic biomarkers, * measures of autonomic dysfunction (e.g., heart rate variability), * cardiac function parameters (e.g., echocardiographic strain indices, NT-proBNP), * cognitive and anxiety assessments, * health-related quality of life and lifestyle factors, * adherence to treatment, * and the incidence of recurrent cardiovascular events during follow-up.

Given its exploratory design, the study is not powered to test confirmatory hypotheses. Instead, it is expected to provide novel descriptive data that will inform the design of future confirmatory trials and contribute to the integration of psychosocial screening in cardiology care pathways.

• C-reactive protein (CRP) levels [Срок оценки: Baseline, 3 months, and 12 months]
• Lipid profile [Срок оценки: Baseline, 3 months, and 12 months]
• NT-proBNP levels [Срок оценки: Baseline, 3 months, and 12 months]
• Cardiac function (LVEF and GLS) [Срок оценки: Baseline, 3 months, and 12 months]
• Recurrent Cardiovascular Events [Срок оценки: Up to 12 months]
• Quality of Life assessed with EQ-5D-5L and VAS [Срок оценки: Baseline, 3 months, and 12 months]
• Treatment Adherence [Срок оценки: Baseline, 3 months, 6 months, 9 months, and 12 months]
• Complete blood count (CBC) parameters [Срок оценки: Baseline, 3 months, and 12 months]